MK-677 (Ibutamoren) Guide

MK-677 (ibutamoren) is a non-peptide, orally bioavailable ghrelin mimetic and growth hormone secretagogue receptor (GHSR) agonist. Despite being frequently grouped with SARMs by vendors, it has a completely different mechanism — it does not bind androgen receptors and does not suppress testosterone.

The mechanism works through the ghrelin receptor (GHSR-1a): MK-677 activates this receptor in the pituitary and hypothalamus, triggering a GH pulse and downstream IGF-1 production by the liver. Oral bioavailability is approximately 60–70% with a half-life of roughly 24 hours, enabling stable once-daily dosing — a significant convenience advantage over injectable peptide GHRP stacks which require subcutaneous injection 2–3 times per day.

MK-677 has completed FDA Phase 2 clinical trials for growth hormone deficiency, Alzheimer's-associated muscle wasting, hip fracture recovery, and sarcopenia in elderly populations. While not FDA-approved for consumer use, this clinical data provides a meaningful safety and efficacy reference. As a research compound, it is sold legally in many countries without a prescription, though regulatory status varies.

The standard research dose range is 10–25mg once daily. Most users start at 10mg and assess IGF-1 levels at 12 weeks before considering an increase. Taking MK-677 in the evening, 30–60 minutes before sleep, is the preferred protocol: this coincides with the natural sleep-associated GH pulse and amplifies it, improving slow-wave and REM sleep architecture as a downstream effect.

Side effects with MK-677 are predictable and largely dose-dependent. The most common is increased appetite — a direct consequence of ghrelin receptor agonism (ghrelin is the hunger hormone). Water retention is common in the first 4–8 weeks and typically diminishes as the body adapts. At higher doses (20–25mg), there is a risk of mild insulin resistance and potential for elevated fasting blood glucose.

Bloodwork protocol: Check IGF-1 at baseline before starting, then again at 12 weeks on-protocol. The target is the upper quartile of the normal age-adjusted range — not above the range. Supraphysiologic IGF-1 is associated with theoretical cancer risks (similar to exogenous HGH), so monitoring is essential. A fasting glucose or HbA1c is also prudent at 12 weeks if you have any insulin sensitivity concerns.

Unlike SARMs and anabolic steroids, MK-677 does not suppress the hypothalamic-pituitary-gonadal (HPG) axis. No post-cycle therapy (PCT) is needed. Testosterone levels are not affected. Natural GH production also recovers within days of discontinuation.

The main alternative to MK-677 for GH axis support is a CJC-1295 + Ipamorelin subcutaneous peptide stack. Both approaches increase GH and IGF-1, but differ significantly in practice:

• •MK-677: Oral pill, once daily, no injection equipment, ~$50–150/month for research-grade compound, convenient for travel and daily compliance.
• •CJC-1295 + Ipamorelin: Subcutaneous injection 2–3 times per day, requires reconstitution and refrigeration, more physiologically pulsatile GH release pattern, often considered more "natural" in timing.
• •IGF-1 Response: Peptide stacks are generally considered more controllable; MK-677's IGF-1 elevation is sustained rather than pulsatile. Clinical data suggests MK-677 raises IGF-1 by 30–60% depending on dose.
• •Combination: Some advanced users combine MK-677 at 10mg (for sleep/baseline IGF-1 support) with occasional peptide injections — but this requires careful IGF-1 monitoring to avoid exceeding normal range.